Venture(US:VEMLY) Sou Hu Cai Jing·2025-09-03 12:25Core Viewpoint - Beijing Simu Ruike Pharmaceutical Technology Co., Ltd. (Simu Ruike) is preparing for an IPO on the Beijing Stock Exchange after completing the IPO counseling record with the Beijing Securities Regulatory Bureau, with CITIC Securities as the counseling institution [1][2]. Company Overview - Simu Ruike was established on May 9, 2008, with a registered capital of 63.84 million yuan, located in Huairou District, Beijing [1][2]. - The company specializes in large-sample, multi-center clinical trial design, operation, data management, and statistical professional services as a Contract Research Organization (CRO) [2]. Shareholding Structure - The controlling shareholder is Beijing Simu Wansheng Management Consulting Co., Ltd., holding 18.58% of the shares [1][2]. - The chairman and general manager, Wei Pengchong, directly holds 12.60% of the shares and controls a total of 43.24% of the voting rights through various holdings [2][3]. Financial Performance - For the fiscal years 2023 and 2024, the company reported revenues of 445.93 million yuan and 417.61 million yuan, respectively [5]. - The net profits for the same years were 95.12 million yuan and 101.66 million yuan, indicating an increase in profit despite a decrease in revenue for 2024 [5]. - The comprehensive gross profit margin improved from 37.50% in 2023 to 43.00% in 2024 [5].